CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SCD and Standard Review for TDT- -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT- -Enrollment and dosing ongoing for CTX110®, targeting CD19+ B-cell malignancies, and CTX130™, targeting CD70 for the treatment of T cell lymphomas- -Enrollment ongoing and dosing initia

Related Keywords

San Francisco ,California ,United States ,United Kingdom ,Switzerland ,Massachusetts ,Boston ,London ,City Of ,Susan Kim ,Samarth Kulkarni ,Rachel Eides ,European Medicines Agency ,Regulatory Agency ,European Hematology Association ,Vertex Pharmaceuticals ,Nasdaq ,European Commission ,Therapeutics Inc ,Exchange Commission ,Drug Administration ,Viacyte Inc ,Biologics License Applications ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Priority Review ,Standard Review ,Chief Executive Officer ,Prescription Drug User Fee Act ,Fast Track ,Regenerative Medicine Advanced Therapy ,Orphan Drug ,Rare Pediatric Disease ,Orphan Drug Designation ,Innovation Passport ,Innovative Licensing ,Access Pathway ,Accounts Receivable ,New England Journal ,Priority Medicines ,Mycosis Fungoides ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended June ,Crispr Therapeutics ,Adt ,Fda ,Clinical Trial ,